The primary difference between a biomarker and a surrogate endpoint is that a biomarker is a “candidate” surrogate marker. In contrast, a surrogate marker is a test used and taken to measure the effects of a specific treatment. In orphan diseases and precision medicine, developing a biomarker plan during translation into early clinical development moves […]
Tagged: Strategies for Orphan Diseases
Interest is increasing rapidly in using surrogate endpoints as primary measures of the effectiveness of investigational drugs in definitive drug trials. Learn more at bbcrconsulting.com.
July 26th, 2023 | Strategies for Orphan DiseasesWelcome to BBCR’s next generation website! We invite you to come explore our new site, redesigned to provide a clear overview of how BBCR can help you with early clinical development, rare disease and orphan drug solutions.
April 18th, 2023 | Strategies for Orphan DiseasesWe are pleased to share with you our newly enhanced website. Over the past several months, our team has carefully reviewed our processes, capabilities, and offerings in order to provide you with the clearest overview of how we help our clients. BBCR is dedicated to supporting pharmaceutical innovators in the specialized rare diseases and orphan […]